Akari Therapeutics plc ADR (0.01 USD) (AKTX) is a publicly traded Healthcare sector company. As of October 13, 2026, AKTX trades at $8.25 with a market cap of $20.04M and a P/E ratio of 0.00. AKTX moved +0.00% today. Year to date, AKTX is -26.12%; over the trailing twelve months it is -77.04%. Its 52-week range spans $3.02 to $69.20. Analyst consensus is strong buy with an average price target of $25.50. Rallies surfaces AKTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AKTX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AKTX recently traded at $8.25. Market cap is $20.04M. P/E ratio is 0.00. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $8.25 |
| Market Cap | $20.04M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $69.20 |
| 52-Week Low | $3.02 |
| Volume | 10.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-17.30M |
| Gross Margin | 0.00% |
3 analysts cover AKTX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.50.